UWA-001 (also known as α-phenyl-MDMA and methylenedioxymephenidine) is a phenethylamine derivative invented at the University of Western Australia as non-toxic alternative to 3,4-methylenedioxy-N-methylamphetamine (MDMA) and researched as a potential treatment for Parkinson's disease.[1]
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H17NO2 |
Molar mass | 255.317 g·mol−1 |
3D model (JSmol) | |
| |
|
It has a 5-HT2A receptor affinity of 1.2 μM (~10-fold increase compared to MDMA), 1.3 μM for the serotonin transporter (~4-fold decrease compared to MDMA), 13.4 μM for the norepinephrine transporter (~26-fold increase compared to MDMA) and virtually no affinity for the dopamine transporter (>50 μM).[1]
Unlike MDMA and para-methoxyamphetamine (but similarly to ketamine),[2] UWA-001 increases prepulse inhibition and was therefore considered to be non-psychoactive, though it was not assayed at other binding sites.[3] It is toxic to the SH-SY5Y cell line at high concentrations, however significantly less toxic than MDMA at all concentrations tested.[3]
UWA-001 is structurally related to the diarylethylamines lefetamine (a stimulant and opioid) and the dissociative anesthetic ephenidine, which acts as a NMDA receptor antagonist.
See also
edit- AD-1211
- Diphenidine
- MBDP (UWA-091)
- Methoxphenidine
- MT-45
- UWA-101
- Mdo-npa (methylenedioxy increases the bioavailability and duration, relative to the venerable dopaminergic agonist, apomorphine).
References
edit- ^ a b Johnston TH, Millar Z, Huot P, Wagg K, Thiele S, Salomonczyk D, et al. (May 2012). "A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates". FASEB Journal. 26 (5): 2154–63. doi:10.1096/fj.11-195016. PMID 22345403. S2CID 37589231.
- ^ Abel KM, Allin MP, Hemsley DR, Geyer MA (May 2003). "Low dose ketamine increases prepulse inhibition in healthy men". Neuropharmacology. 44 (6): 729–37. doi:10.1016/S0028-3908(03)00073-X. PMID 12681371. S2CID 25706718.
- ^ a b Gandy MN, McIldowie M, Lewis K, Wasik AM, Salomonczyk D, Wagg K, et al. (2010). "Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity". MedChemComm. 1 (4): 287–93. doi:10.1039/C0MD00108B.